KRAS G12D Inhibitor INCB186748

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable inhibitor of the oncogenic KRAS substitution mutation G12D, with potential antineoplastic activity. Upon oral administration, KRAS G12D inhibitor INCB186748 selectively targets, binds to and inhibits the activity of the KRAS G12D mutant, thereby preventing KRAS G12D-mediated signaling and the activation of downstream survival pathways. This leads to an inhibition of the growth of tumor cells that overexpress KRAS G12D. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell proliferation, invasion, and metastasis.

**Synonyms:** - INCB 186748 - INCB-186748 - INCB186748